Abstract
Allergic rhinitis (AR) is one of the most common chronic diseases in all age groups. It is an IgE-mediated allergic inflammation of the nasal airways and is characterized by sneezing, swelling and inflammation of the nasal mucosa as well as itchy and watery eyes. It is a global health problem and a burdensome disorder affecting many people from childhood to adulthood. The prevalence of childhood AR shows wide variation throughout the world, ranging from 0.8 to 45%. The prevalence rates for different regions of Turkey ranges from 2.9 to 44%. The aim of the present review is to provide an update on AR treatment and diagnosis. Because of its burden on patient’s lives and its impact on asthma, AR should be taken care of properly with effective and safe treatments. Second-generation antihistamines and intranasal steroids represent the milestone of AR therapy. New formulations of available drugs (rupatadine oral solution, ebastine fast-dissolving tablets, combination of intranasal fluticasone propionate and azelastine hydrochloride), recently discovered molecules (ciclesonide, bilastine, roflumilast, etc.), immunologic targets (omalizumab) and unconventional treatments (homeopathic treatments) are representing new frontiers in AR management. An accurate diagnosis of AR is also crucial to increase treatment success. Further promising improvements in diagnostics are expected from recombinant allergen diagnostics identifying particular molecules of risk. Purified native or recombinant allergens, identifying the individual molecules to which patients are sensitized, can be determined by molecular or component resolved diagnostics. These may decrease the need for provocation testing and improve the specificity of allergen immunotherapy. Different methods to measure nasal nitric oxide (nNO) levels are currently being revealed. Decreased nNO concentration is also typical of cystic fibrosis, even though nNO is not as low as in primary ciliary dyskinesia. The clinical utility of nNO remains to be established in upper airway disorders such as AR.
Highlights
Bu derleme makalesinde önce allerjik rinit (AR)’in tanımı, sıklığı, fizyopatolojisinden kısaca bahsedildikten sonra, teşhis yöntemleri ve tedavisindeki yenilikler son literatür verileri ışığında detaylıca anlatılacaktır
The aim of the present review is to provide an update on Allergic rhinitis (AR) treatment and diagnosis
Second-generation antihistamines and intranasal steroids represent the milestone of AR therapy
Summary
Allerjik rinit (AR) tüm yaş gruplarında görülen en sık ve kronik hastalıklardan biridir. Fakat mevcut ilaçların yeni formülasyonları (rupatadin oral solusyonu, hızlı çözünen ebastin tablet ve intranazal flutikazon propionat ve azelastin hidroklorit kombinasyonu vb.), yeni keşfedilmiş moleküller (siklesonid, bilastin, roflumilast vb.), immünolojik hedefi olan tedaviler (omalizumab gibi) ve klasik olmayan tedaviler (homeopatik yöntemler gibi) AR tedavisinde yeni ufukları temsil etmektedir. Allerjik rinitin doğru teşhis edilmesi tedavi başarısında esastır. Hastaların duyarlı olduğu kişisel molekülleri tanımlayan pür doğal ve rekombinan allerjenler moleküler ya da belirlenmiş komponentin teşhis yöntemiyle saptanabilir. Belirlenmiş komponente dayalı teşhis yöntemi provokasyon testine olan ihtiyacı azaltabilir ve allerjen immünoterapisinin özgünlüğünü artırabilir. Nazal nitrik oksit (nNO) düzeyini ölçmekte günümüzde değişik yöntemler vardır. Azalmış nNO, kistik fibroz için tipik olmakla beraber, primer silyer diskinezide olduğu kadar düşük değildir. Anahtar kelimeler: Allerjik rinit, idiopatik rinit, nazal nitrik oksit, immünoterapi
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
